Barely or fairly balancing drug risks? Content and format effects in direct-to-consumer online prescription drug promotions

Psychology and Marketing

Volumn 25, Issue 7, 2008, Pages 675-691

  Kees, Jeremy ^a   Bone, Paula Fitzgerald ^b   Kozup, John ^a   Ellen, Pam Scholder ^c  

^a VILLANOVA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 49049098691     PISSN: 07426046     EISSN: 15206793     Source Type: Journal    
DOI: 10.1002/mar.20231     Document Type: Article

References (40)

1. Aikin, K. J. (2006, November 20). Social Science Analyst, Division of Drug Marketing, Advertising, and Communications, Center for Drug Evaluation and Research, Food and Drug Administration. Personal communication.
2. Baron, J., & Ritov, I. (2004). Omission bias, individual differences, and normality. Organizational Behavior and Human Decision Processes, 94, 74-85.
3. CBS Television Network. (1984). The CBS consumer model: A study of attitudes, concerns, and information needs for prescription drugs and mental illnesses. New York: CBS Television Network Sales/Marketing Services.
4. Chandran, S., & Menon, G. (2004). When a day means more than a year: Effects of temporal framing on judgments of health risk. Journal of Consumer Research, 31, 375-389.
5. Davis, J. J. (2000). Riskier than we think? The relationship between risk statement completeness and perceptions of direct to consumer advertised prescription drugs. Journal of Health Communication, 5, 349-369.
6. Dhar, R. (1997). Consumer preference for a no-choice option. Journal of Consumer Research, 24, 215-231.
7. Fischhoff, B., Riley, D., Kovacs, D., & Small, M. (1998). What information belongs in a warning? Psychology & Marketing, 15, 663-687.
8. Food and Drug Administration. (1999). Guidance for industry consumer-directed broadcast advertisements, http://www.fda.gov/cber/gdlns/ advrts.pdf.
9. Food and Drug Administration. (2004, November 17). Black box warning added concerning long-term use of Depo-Provera contraceptive injection, http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html.
10. Food and Drugs. (2000). 21 C.F.R. http://www.access.gpo.gov/nara/cfr/ waisidx_00/21cfrv1_00.html.
11. Fox, S. (2006, October 29). Online health search 2006. Pew Internet & American Life Project. http://www.pewinternet.org/pdfs/PIP_Online_Health_2006. pdf.
12. Gibbons, R. D., Hur, K, Bhaumik, D. K., & Mann, J. J. (2006). The relationship between antidepressant prescription rates and rate of early adolescent suicide. The American Journal of Psychiatry, 163, 1898-1904.
13. Harris Interactive. (2004, December 10). Nearly half of U.S. adults closely following news coverage of Vioxx withdrawal, http://www. harrisinteractive.com/news/allnewsbydate.asp?NewsID=872.
14. Keller, P. A., Lipkus, I. M., & Rimer, B. K. (2003). Affect, framing, and persuasion. Journal of Marketing Research, 40, 54-64.
15. Kelley, C. A., Gaidis, W. C., & Reingen, P. H. (1989). The use of vivid stimuli to enhance comprehension of the content of product warning messages. Journal of Consumer Affairs, 23, 243-266.
16. Keown, C., Slovic, P., & Lichtenstein, S. (1984). Influence of risk information about side effects on perceived risk of prescription drugs. Health Marketing Quarterly, 1, 111-123.
17. Kozup, J., Burton, S., & Greyer, E. H. (2006). The provision of trans fat information and its interaction with consumer knowledge. Journal of Consumer Affairs, 40, 163-176.
18. Medco Health Solutions. (2006). New data shows adults continue to outpace children in growth of ADHD medication use. http://phx.corporate-ir.net/phoenix. zhtml?c=131268&p=irol-newsArticle&ID=833839&highlight=.
19. Menon, G., Block, L. G., & Ramanathan, S. (2002). We're at as much risk as we are led to believe: Effects of message cues on judgments of health risk. Journal of Consumer Research, 28, 533-549.
20. Morris, L. A., Brinberg, D., & Plimpton, L. (1984). Prescription drug information for consumers: An experiment of source and format. Current Issues and Research in Advertising, 7, 65-78.
21. Morris, L. A., Ruffner, M., & Klimberg, R. (1985). Warning disclosures for prescription drugs. Journal of Advertising Research, 25, 25-32.
22. Morris, L. A., Brinberg, D., Klimberg, R., Rivera, C., & Millstein, L. G. (1986). Miscomprehension rates for prescription drug advertisements. Current Issues and Research in Advertising, 9, 93-117.
23. Morris, L. A., Mazis, M. B., & Brinberg, D. (1989). Risk disclosures in televised prescription drug advertising to consumers. Journal of Public Policy & Marketing, 8, 64-80.
24. O'Rourke, J. S., IV. (2006). Merck and Co., Inc.: Communication lessons from the withdrawal of Vioxx. www.reputationinstitute.com/members/nyc06/ORourke. pdf.
25. Ritov, I., & Baron, J. (1990). Reluctance to vaccinate: Omission bias and ambiguity. Journal of Behavioral Decision Making, 3, 263-277.
26. Scammon, D. (1977). Information load and consumers. Journal of Consumer Research, 4, 148-155.
27. Schwartz, N. (2004). Metacognitive experiences in consumer judgment and decision making. Journal of Consumer Psychology, 14, 332-348.
28. Smith, C. (2006, August 29). Madigan, public citizen, petition FDA for "black box" warning regarding potential adverse effects of certain popular antibiotics, http://www.illinoisattorneygeneral.gov/pressroom/2006_08/ 20060829.html.
29. Spranca, M., Minsk, E., & Baron, J. (1991). Omission and commission in judgment and choice. Journal of Experimental Social Psychology, 27, 76-105.
30. Stewart, D. W., & Martin, I. M. (1994). Intended and unintended consequences of warning messages: A review and synthesis of empirical research. Journal of Public Policy & Marketing, 13, 1-19.
31. Stewart, D. W., & Martin, I. M. (2004). Advertising disclosures: Clear and conspicuous or understood and used? Journal of Public Policy & Marketing, 23, 183-192.
32. Stewart, D. W., Folkes, V. S., & Martin, I. M. (2001). Consumer response to warnings and other types of product hazard information: Future public policy and research directions. In P. Bloom & G. Gundlach (Eds.), Handbook of marketing and society (pp. 335-371). Thousand Oaks, CA: Sage Publications.
33. Taylor, V. A., & Bower, A. B. (2004). Improving product instruction compliance: "If you tell me why, I might comply." Psychology & Marketing. 21, 229-248.
34. Tucker, G. K., & Smith, M. C. (1987). Direct-to-consumer advertising: Effects of different formats of warning information disclosure on cognitive reactions of adults. Journal of Pharmaceutical Marketing & Management, 2, 27-41.
35. Vigilante, W. J., & Wogalter, M. S. (2003, September 23). DTC advertising of prescription medications on the WWW: Assessing the communication of risks & benefits. Presentation to the FDA Office of Medical Policy Division of Drug Marketing, Advertising, and Communications (DDMAC). http://www.fda.gov/cder/ddmac/P7Vigilante/sld001.htm.
36. Viscusi, W. K., Magat, W. A., & Huber, J. (1986). Informational regulation of consumer health risks: An empirical evaluation of hazard warnings. Rand Journal of Economics, 17, 351-365.
37. Williams, L. (2006). Antidepressants reduce suicide in children despite FDA warning. Ivanhoe newswire. http://www.drkoop.com/newsdetail/93/8014812.html.
38. Wogalter, M. S., Smith-Jackson, T. L., Mills, B. J., & Paine, C. S. (2002). The effects of print format in direct-to-consumer prescription drug advertisements on risk knowledge and preference. Drug Information Journal, 36, 693-705.
39. Woodcock, J. (2003). Testimony from FDA regulates prescription drug promotion: Hearing before the Special Committee on Aging, United States Senate, 108th Congress. http://www.fda.gov/ola/2003/AdvertisingofPrescriptionDrugs0722. html.
40. Zuckerman, A., & Chaiken, S. (1998). A heuristic-systematic processing analysis of the effectiveness of product warning labels. Psychology & Marketing, 15, 621-643.